T1	Participants 64 90	autism spectrum disorders.
T2	Participants 305 338	in brains of patients with autism
T3	Participants 450 462	exploration.
T4	Participants 463 523	Twenty children with autism spectrum disorder age 4-12 years
T5	Participants 811 889	RESULTS Eighteen participants (10 mecamylamine, 8 placebo) completed the study
